Pensionfund Sabic Lowers Position in Hologic, Inc. (NASDAQ:HOLX)

Pensionfund Sabic reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 18.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,800 shares of the medical equipment provider’s stock after selling 3,200 shares during the period. Pensionfund Sabic’s holdings in Hologic were worth $1,124,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Innealta Capital LLC acquired a new position in shares of Hologic in the 2nd quarter valued at $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic in the 1st quarter valued at $37,000. Sunbelt Securities Inc. purchased a new stake in Hologic in the 2nd quarter valued at $37,000. Cranbrook Wealth Management LLC acquired a new stake in Hologic during the 2nd quarter worth $47,000. Finally, Mather Group LLC. purchased a new position in Hologic during the 1st quarter worth $48,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the subject of several analyst reports. Evercore ISI upped their price target on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. Leerink Partners lowered their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday. Mizuho increased their price target on shares of Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Finally, JPMorgan Chase & Co. lifted their price objective on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.50.

Insiders Place Their Bets

In other news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now owns 10,476 shares in the company, valued at $858,927.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now owns 10,476 shares in the company, valued at $858,927.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,280 shares of company stock worth $1,469,973. Corporate insiders own 1.75% of the company’s stock.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $79.92 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The firm has a market capitalization of $18.56 billion, a PE ratio of 27.18, a P/E/G ratio of 2.89 and a beta of 0.98. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $84.67. The business’s fifty day moving average price is $81.14 and its two-hundred day moving average price is $77.55.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period in the prior year, the company posted $0.93 EPS. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, research analysts expect that Hologic, Inc. will post 4.09 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.